首页> 外国专利> NEW RECOMBINANT ANTIBODY AGAINST HUMAN CARBONIC ANHYDRASE XII

NEW RECOMBINANT ANTIBODY AGAINST HUMAN CARBONIC ANHYDRASE XII

机译:抗人类碳酸酐酶XII的新重组抗体

摘要

A new recombinant antibody that targets transmembrane enzyme carbonic anhydrase XII was produced. The expression of the enzyme increases in certain types of cancer cells. Recombinant antibody produced is a new protein, which so far has not been described in scientific literature. First, cell line (hybridomas) producing monoclonal antibody to carbonic anhydrase XII was developed. Copy DNA sequences encoding an immunoglobulin variable regions were cloned from hybridoma cells, recombinant plasmids were created and recombinant antibody expression was attained. Well-known methods, such as hybridoma technology, genetic engineering, protein purification, immunochemical analysis were used for antibody development. Recombinant antibody produced may be applied in medical and biopharmaceutical branches due to capacity to inhibit growing of cancer cells containing carbonic anhydrase XII.
机译:产生了靶向跨膜酶碳酸酐酶XII的新型重组抗体。该酶的表达在某些类型的癌细胞中增加。产生的重组抗体是一种新蛋白质,到目前为止,科学文献中尚未对此进行描述。首先,开发了产生针对碳酸酐酶XII的单克隆抗体的细胞系(杂交瘤)。从杂交瘤细胞中克隆编码免疫球蛋白可变区的复制DNA序列,创建重组质粒并获得重组抗体表达。杂交瘤技术,基因工程,蛋白质纯化,免疫化学分析等众所周知的方法被用于抗体开发。产生的重组抗体由于具有抑制含有碳酸酐酶XII的癌细胞生长的能力,因此可以应用于医疗和生物制药领域。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号